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Abstract 24 
Background 25 
Human papillomaviruses (HPV) are a heterogeneous group of viruses classified into five 26 
genera. The beta-HPV type (beta-PV) infection is very common but mostly asymptomatic in 27 
immunocompetent individuals. However, beta-PVs play a role in epidermodysplasia 28 
verruciformis and possibly in non-melanoma skin cancer. Head and neck cancer (HNC) is a 29 
common cancer type worldwide and high-risk alpha-PV involvement in HNC has been 30 
extensively studied but beta-PV types have rarely been the focus of such studies.  31 
Objectives 32 
To evaluate the prevalence of beta-PV types in HNC, subjects with non-malignant or 33 
potentially pre-malignant oral lesions, and healthy controls. 34 
Study design 35 
The frequency of different beta-PVs in samples from oral (n=35) and oropharyngeal (n=35) 36 
cancer patients, gender- and age-matched healthy controls (n=70), and subjects with various 37 
non-malignant or potentially pre-malignant oral lesions (n=102) was assessed by a highly 38 
sensitive, bead-based, multiplex genotyping assay.  39 
Results 40 
Overall, 54.8% of all tested samples contained at least one beta-PV type. Even though the 41 
correlation between types found in lavage and tissue specimens from cancer patients was low, 42 
there was a large statistically significant difference between oropharyngeal cancer patients 43 
and matched controls for HPV5 (P=0.003; OR=15.58) and between both oral (P=0.026; 44 
OR=5.7) and oropharyngeal cancer patients (P=0.002; OR=25.5) and controls for HPV122. In 45 
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addition, there was no correlation between the prevalence of alpha and beta-PVs in the study 46 
patients. 47 
Conclusion 48 
The data describes the prevalence of beta-PVs in HNC. The significant association of 49 
HPV122 with HNC might warrant further study as this type has not been extensively studied 50 
so far. 51 
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Introduction 68 
Human papillomaviruses (HPV) are a large and heterogeneous group of viruses of the 69 
Papillomaviridae family, which are classified into five genera. Currently, more than 200 HPV 70 
types have been identified [1]. A subset of mucosal alpha-genus papillomaviruses (alpha-PV) 71 
classified as high-risk human papillomaviruses (HR-HPV) cause almost all cervical and a part 72 
of vaginal, vulvar, penile, anal, and oropharyngeal cancers. Low-risk alpha-PVs (LR-HPV) 73 
are involved in anogenital condyloma in men and women as well as in laryngeal 74 
papillomatosis [2]. HPV infection of the skin, usually with the beta-genus papillomaviruses 75 
(beta-PV), is common but is mostly asymptomatic in immunocompetent individuals.  In 2009, 76 
the International Agency for Research on Cancer (IARC) classified two beta-PVs, HPV5 and 77 
HPV8, as possibly carcinogenic in epidermodysplasia verruciformis patients, who have a high 78 
susceptibility to beta-PV infection and skin cancer [1–5].  79 
Head and neck cancer (HNC) is a diverse group of malignancies encompassing cancers of the 80 
upper aerodigestive tract, paranasal sinuses, and salivary glands [6]. The most common 81 
histological type is squamous cell carcinoma (SCC). HR-HPVs are implicated in the 82 
development of a subset of the HNCs [7], most notably in the tonsils.  According to a recent 83 
comprehensive review, in oral samples from healthy individuals, alpha-PVs can be found in 84 
approximately 4.5% of cases [8]; however, other studies have shown slightly greater 85 
prevalence rates of 5-12% [9- 12]. There are also studies showing higher prevalence of alpha-86 
PVs in potentially premalignant oral lesions [12, 13]. 87 
Since the initial discovery that certain HNCs could be associated with HPV [14], the 88 
involvement of HR-HPVs in HNC has been extensively studied [15–17]. However, HPVs of 89 
beta- and gamma-genera (cutaneous types) have rarely been the focus of such studies [18–20]. 90 
Cutaneous HPVs have been frequently detected in oral cavity specimens [19, 20], but the 91 
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prevalence of cutaneous types in cancer tissues has been inconsistent [18, 21]. Those studies 92 
mostly used the established FAP59/FAP64 primers amplifying the L1 region of 67 different 93 
types [22] or CP65/CP70 and CP66/CP69 nested system amplifying the L1 region of at least 94 
19 HPVs [23].  95 
Herein, the frequency of different beta-PVs in samples from the oral cavity and oropharyngeal 96 
cancer patients as well as from clinically distinct oral lesions and gender- and age-matched 97 
healthy controls is assessed by a highly sensitive, type-specific, bead-based, multiplex 98 
genotyping assay (TS-MPG), which is suitable for the detection of low-copy number HPV 99 
cutaneous types and multiple infections in epidemiological analyses [24–27]. 100 
 101 
Materials and methods 102 
Study population 103 
Samples from patients with primary SCC of the oral cavity (n=35) or oropharynx (n=35), 104 
collected [28] from 2001 to 2007 in the Department of Otolaryngology and Head and Neck 105 
Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital 106 
Motol, with signed informed consent forms, were selected for analysis. For each patient, a 107 
control oral rinse sample from a gender- and age-matched healthy individual was collected 108 
(n=70). In addition, oral swab samples from 102 individuals with clinically distinct oral 109 
lesions (potentially malignant lesions: 40.2% with leukoplakia, 30.4% with lichen ruber 110 
planus, and 2.9% other lesions including two cases of erythroleukoplakia and one case of 111 
erythroplakia; benign proliferative lesions: 10.8% papilloma and 18.6% other lesions 112 
including stomatitis simplex, verruca, chelitis, and aphtae), collected during dental 113 
examination at the Department of Oral Medicine, School of Dental Medicine, University of 114 
6 
 
Zagreb from 1995 to 2011 [12], were included in this study. The study received the official 115 
institutional and ethical approval from the participating institutions.  116 
 117 
Patient samples 118 
From oral/oropharyngeal cancer patients, both oral exfoliated cells (lavage) and tumor biopsy 119 
specimens were collected as described in detail previously [28]. The corresponding controls 120 
provided only lavages. DNA was extracted from a minimum of 250,000 cells using Puregene 121 
Core Kit A (Gentra Qiagen, Hilden, Germany) and from two 20 µm formalin fixed paraffin 122 
embedded (FFPE) biopsy sections using the Ambion RecoverAllTM Total Nucleic Acid 123 
Isolation Kit for FFPE Tissues (Applied Bioscience, Austin, TX). A cytobrush (Medscand 124 
AB, Sweden) was used for scraping the site(s) of clinically visible lesions, which were 125 
classified either by morphology or clinical diagnosis [12] and further confirmed by 126 
histopathology [29]. DNA from the collected samples in TES buffer was extracted by the high 127 
salt method [12].  128 
 129 
Beta-PV detection by Luminex 130 
All samples were analyzed for the presence of beta-PV types using the TS-MPG assay (IARC, 131 
Lyon, France), which combines multiplex PCR with a bead-based Luminex technology [24, 132 
30]. This assay detects 43 different beta-PV types, with the human beta-globin gene serving 133 
as a control. Following PCR, 10 µl of each reaction mixture was analyzed using the Luminex 134 
instrument (Luminex Corporation, Austin, TX) as described previously [25,31].  135 
 136 
 137 
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Data analysis 138 
Samples with multiple infection are those with two or more HPV types detected. Such 139 
samples were counted as positive for each type of HPV found. The type-specific HPV 140 
prevalence is expressed as the percentage of all subjects tested for HPV, and thus represents 141 
the HPV prevalence in both single and multiple infections. The odds ratio (OR) and chi-142 
square test values were calculated in Microsoft Excel (v. 2013). 143 
 144 
Results 145 
In this study, 242 patients and controls were tested for beta-PV presence. Overall 312 samples 146 
were analysed. Oral cancer patients (median age 55 years, range 35-84) were mostly male 147 
(80%), as were the oropharyngeal cancer patients (68.6%, median age 57 years, range 35-75 148 
years). Only 32.4% of patients with oral lesions (median age 55 years, range 16-87) were 149 
male. 150 
Thirteen samples in which the beta-globin and HPV amplification was unsuccessful were 151 
removed from further calculations. Those were six oral cancer samples, a lavage from one 152 
oral cancer patient, three lavages from oropharyngeal controls, and three swabs of oral 153 
lesions. 154 
The overall beta-PV positivity is summarized in Figure 1. Table 1 shows detailed comparison 155 
of the prevalence of beta-PVs in different groups of patients, matched control group, and 156 
different types of samples from the same patient. The oral lesions group contained the most of 157 
beta-PV positive samples (67.7%), with the greatest average number of HPV types (5.1) per 158 
positive sample, followed by the oral cancer group (55.2%) and oropharyngeal tumor group 159 
(45.7%). The lowest positivity rate was found in the lavage samples from patients with oral 160 
cancer (17.6%), with the lowest average number of HPV types (1.2) per sample. In contrast, 161 
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the oral lavage samples from patients with oropharyngeal cancer were very often positive 162 
(60%). The prevalence rate of beta-PV types in the control group was also very high (56.7%).  163 
The beta-PV positivity per patient was evaluated by combining the data from lavage and/or 164 
tissue samples of the same patient (Table 1; “Person” column). If either his/her lavage or 165 
tissue sample was positive for a beta-PV type, the study subject was considered as positive for 166 
that particular beta PV-type. Overall, the beta-PV type most commonly detected in study 167 
subjects was HPV5 (35/236; 14.8%), but it was only the third most common one in oral 168 
cancer (11.4%) after HPV122 (25.7%) and HPV151 (17.1%). 169 
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Table 1. Beta-PV types detected in different study patient groups and gender- and age-matched controls.  
 
Control 
(n=67) 
Oral cancer Oropharyngeal cancer 
Oral lesion 
(n=99)  Lavage 
(n=34) 
Tissue 
(n=29) 
Person** 
(n=35) 
Lavage 
(n=35) 
Tissue   
(n=35) 
Person** 
(n=35) 
HPV type* N [%] N [%] N [%] N [%] N [%] N [%] N [%] N [%] 
Positive 38 (56.7) 6 (17.6) 16 (55.2) 22 (62.9) 21 (60.0) 16 (45.7) 29 (82.9) 67 (67.7) 
Single 16 (23.9) 5 (14.7) 5 (17.2) 8 (22.9) 7 (20.0) 8 (22.9) 7 (20.0) 16 (16.2) 
Multiple 22 (32.8) 1 (2.9) 11 (37.9) 14 (40.0) 14 (40.0) 8 (22.9) 22 (62.9) 51 (51.5) 
HPV5 6 (9.0) 0 (0.0) 4 (13.8) 4 (11.4) 6 (17.1) 5 (14.3) 11 (31.4) 14 (14.1) 
HPV8 7 (10.4) 0 (0.0) 1 (3.4) 1 (2.9) 4 (11.4) 4 (11.4) 7 (20.0) 7 (7.1) 
HPV9 0 (0.0) 0 (0.0) 1 (3.4) 1 (2.9) 1 (2.9) 1 (2.9) 2 (5.7) 9 (9.1) 
HPV12 4 (6.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (8.6) 0 (0.0) 3 (8.6) 9 (9.1) 
HPV14 1 (1.5) 0 (0.0) 1 (3.4) 1 (2.9) 2 (5.7) 1 (2.9) 3 (8.6) 2 (2.0) 
HPV15 0 (0.0) 1 (2.9) 0 (0.0) 1 (2.9) 2 (5.7) 1 (2.9) 3 (8.6) 5 (5.1) 
HPV17 2 (3.0) 1 (2.9) 0 (0.0) 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 7 (7.1) 
HPV19 3 (4.5) 2 (2.7) 0 (0.0) 2 (5.7) 0 (0.0) 0 (0.0) 0 (0.0) 9 (9.1) 
HPV20 4 (6.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (6.1) 
HPV21 2 (3.0) 1 (2.9) 1 (3.4) 2 (5.7) 2 (5.7) 0 (0.0) 2 (5.7) 12 (12.1) 
HPV22 3 (4.5) 0 (0.0) 0 (0.0) 0 (0.0) 4 (11.4) 2 (5.7) 6 (17.1) 12 (12.1) 
HPV23 2 (3.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.7) 0 (0.0) 2 (5.7) 10 (10.1) 
HPV24 7 (10.4) 0 (0.0) 0 (0.0) 0 (0.0) 3 (8.6) 2 (5.7) 5 (14.3) 17 (17.2) 
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HPV25 1 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (3.0) 
HPV36 5 (7.5) 1 (2.9) 0 (0.0) 1 (2.9) 1 (2.9) 0 (0.0) 1 (2.9) 18 (18.2) 
HPV37 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.0) 
HPV38 8 (11.9) 0 (0.0) 0 (0.0) 0 (0.0) 5 (14.3) 0 (0.0) 5 (14.3) 18 (18.2) 
HPV47 2 (3.0) 0 (0.0) 3 (10.3) 3 (8.6) 4 (11.4) 4 (11.4) 8 (22.9) 8 (8.1) 
HPV49 4 (6.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9) 1 (2.9) 2 (5.7) 15 (15.2) 
HPV75 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.0) 
HPV76 6 (9.0) 0 (0.0) 4 (13.8) 4 (11.4) 3 (8.6) 2 (5.7) 4 (11.4) 10 (10.1) 
HPV80 3 (4.5) 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.7) 0 (0.0) 2 (5.7) 9 (9.1) 
HPV92 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.0) 
HPV93 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9) 0 (0.0) 1 (2.9) 3 (3.0) 
HPV96 4 (6.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (3.0) 
HPV98 2 (3.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (4.0) 
HPV99 1 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 10 (10.1) 
HPV100 5 (7.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9) 1 (2.9) 2 (5.7) 1 (1.0) 
HPV104 1 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.7) 2 (5.7) 2 (2.0) 
HPV105 3 (4.5) 0 (0.0) 2 (6.9) 2 (5.7) 4 (11.4) 2 (5.7) 5 (14.3) 5 (5.1) 
HPV107 3 (4.5) 1 (2.9) 4 (13.8) 4 (11.4) 3 (8.6) 1 (2.9) 4 (11.4) 13 (13.1) 
HPV110 8 (11.9) 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.7) 0 (0.0) 2 (5.7) 12 (12.1) 
HPV111 3 (4.5) 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.7) 3 (8.6) 4 (11.4) 12 (12.1) 
HPV113 0 (0.0) 0 (0.0) 1 (3.4) 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 5 (5.1) 
HPV115 1 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.0) 
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HPV118 1 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
HPV120 3 (4.5) 0 (0.0) 0 (0.0) 0 (0.0) 3 (8.6) 2 (5.7) 5 (14.3) 14 (14.1) 
HPV122 2 (3.0) 0 (0.0) 9 (31.0) 9 (25.7) 4 (11.4) 5 (14.3) 9 (25.7) 9 (9.1) 
HPV124 1 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.7) 2 (5.7) 4 (11.4) 11 (11.1) 
HPV143 2 (3.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (4.0) 
HPV145 5 (7.5) 0 (0.0) 1 (3.4) 1 (2.9) 1 (2.9) 3 (8.6) 3 (8.6) 9 (9.1) 
HPV151 2 (3.0) 0 (0.0) 6 (20.7) 6 (17.1) 1 (2.9) 3 (8.6) 3 (8.6) 14 (14.1) 
*A particular type was counted in each sample (single or multiple infection) positive for that type (maximum attribution) and thus the sum of 
detected types exceeds the total of the samples tested. 
**Lavage and tissue results were aggregated per person tested. 
 
 
 
 
 
12 
 
When the cancer samples were compared to their respective matched controls, the only 1 
statistically significant differences for the oral cancer subset were in the prevalence of 2 
HPV122 (P=0.026; OR=5.71) and HPV24 (P=0.012; OR=0.06), while in the oropharyngeal 3 
cancer subset differed significantly in the prevalence of HPV122 (P=0.002; OR=25.45), 4 
HPV5 (P=0.003; OR=15.58), and HPV47 (P=0.003, OR=21.95). 5 
When all cancer samples were compared with all other non-cancer samples (control and oral 6 
non-cancer lesions), statistically significant differences were observed in the prevalence of 7 
more HPV types: HPV122 (P<0.001; OR=4.97), HPV36 (P=0.011; OR=0.19), HPV47 8 
(P=0.022; OR=2.96), HPV110 (P=0.028; OR=0.22), HPV20 (P=0.037; OR=0.11), HPV99 9 
(P=0.037; OR=0.10), and HPV49 (P=0.044; OR=0.23). However, there were also significant 10 
differences in HPV type specific positivity between the subjects with oral lesions and healthy 11 
controls: HPV9 (P=0.011; OR=14.8), HPV151 (P=0.015; OR=5.6), HPV124 (P=0.016; 12 
OR=8.63), HPV99 (P=0.028; OR=7.75), HPV120 (P=0.04; OR=3.68), HPV36 (P=0.043; 13 
OR=2.89), and HPV21 (P=0.045; OR=4.69).   14 
Another result of particular interest was a low concordance between the typing results of 15 
biopsy tissue and oral rinse samples from the same cancer patient (n=70). Overall, there were 16 
seven (10%) patients who had one of the two samples beta-globin negative and were excluded 17 
from analysis, 32 (45.7%) patients with HPV detected in only one sample and the other 18 
sample being HPV negative, 18 (25.7%) patients whose samples were both HPV negative, , 19 
and finally 13 (18.6%) patients who tested positive for HPV in both types of material. The 20 
low concordance of HPV types in the 13 patients with both samples positive for at least one 21 
HPV type is illustrated in Table 2. 22 
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Table 2. HPV typing concordance between different samples from the same patient (n=13). 
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OPH = oropharyngeal cancer; O = oral cancer; L = lavage fluid, T = tissue  
14 
 
 
Discussion 1 
The alpha-PVs are a well acknowledged etiological factor in the development of some types 2 
of head and neck cancers. However, data on the potential influence of beta-PVs are limited. 3 
The purpose of this study was to provide additional data on the beta-PV prevalence in oral 4 
and oropharyngeal cancers, potentially premalignant lesions, and corresponding controls. To 5 
this end, 35 oral and 35 oropharyngeal cancer cases, 102 patients with pre- and non-malignant 6 
oral mucosa lesions, and 70 healthy controls were evaluated by a highly sensitive TS-MPG 7 
assay for beta-PV genotyping. 8 
In this study, HPV was found in 41.8%, 54.9%, and 67.7% of samples from the oral region of 9 
cancer patients and controls, oropharyngeal region of cancer patients and controls, and oral 10 
region of oral lesion patients, respectively. The high average beta-PV prevalence observed in 11 
this study in any group investigated is difficult to put in context with previous studies. 12 
Koskinen et al. [21] tested 61 HNC tissues with a single-phase FAP59/64 PCR and nested 13 
PCR with primers CP65/70 and CP66/69 to detect cutaneous HPVs but failed to find any. 14 
Lindel et al. [18] have reported HPV in 35.0% of 51 HNC tissues where, aside from HPV6 15 
and HPV16, most of the detected types belonged to the cutaneous types. Bottalico et al. [19] 16 
investigated oral rinse samples from 317 HIV negative and otherwise healthy men by 17 
FAP59/64 primers and hybridization and have found a beta-PV prevalence of 34.0% 18 
(108/317). Paolini et al. [20] tested oral rinse/swab samples from healthy controls, non-19 
malignant lesions, and biopsy material from HNC. They used CP65/CP70 followed by 20 
CP66/CP69 and FAP59/FAP64 primers. The healthy group had 25.0% beta-PV positive 21 
samples, the patients with lesions had the highest beta-PV prevalence (51.0%), and only 22 
20.5% of cancer tissues were beta-PV positive. The authors noted the methodological 23 
differences between their study and all three previous ones and also emphasized that beta-PVs 24 
15 
 
 
are usually present in a very low copy number. Therefore, the higher prevalence of beta-PVs 1 
in our study can be attributed to using a more recent and sensitive genotyping method. It 2 
should also be noted that their control group had an average age of 40.7 years, while our 3 
controls were age matched to the cancer patients and thus had an average age of 56.2 years, 4 
which might have influenced the results [10]. 5 
The overall most common type in the analyzed samples was HPV5 (11.7%). This HPV type 6 
was found in 9.0% samples from the combined control group, of which 11.4% and 31.4% 7 
were detected in oral and oropharyngeal cancer samples, respectively. This HPV type is 8 
grouped as probably carcinogenic and associated with non-melanoma skin cancer [4] but was 9 
also the most common beta-PV type to be found in the oral cavity of healthy people [19]. 10 
Herein, there was a large statistically significant difference between the oropharyngeal cancer 11 
patients and matched controls (P=0.003; OR=15.58), indicating that HPV5 should be studied 12 
more closely. 13 
The second leading beta-PV type in this study was HPV38 (10.4%). It is known to be highly 14 
prevalent in skin cancer [32, 33] but is also very common in the plucked eyebrow hairs of 15 
healthy people [34]. Antibodies against this type are also common in the general population 16 
[35]. Strangely, even though HPV38 was often identified in oral cancer in a previous study 17 
[36], none of the oral cancer patients had this type detectable in either lavage or biopsy 18 
sample in our study. However, comparable rates of the oropharyngeal cancer patients (14.3%) 19 
and controls (11.9%) had this type present in the present study. 20 
The third overall most common beta-PV type was HPV122 (9.7% of samples tested; 12.3% of 21 
individuals tested). Despite the data on this type being scarce, in this study, HPV122 was 22 
found to be statistically significantly associated with both oral (P=0.026; OR=5.7) and 23 
16 
 
 
oropharyngeal (P=0.002; OR=25.5) cancer.  Furthermore, the association was also significant 1 
in the overall comparison of cancer versus all non-cancer samples (including control and non-2 
cancer oral lesions). The lack of other reports of the presence of this HPV type in HNC might 3 
be due to the fact that it was only recently described [1], and some of the methods previously 4 
used for the detection of beta-PVs do not specifically target HPV122.  5 
The prevalence of alpha-PVs in the same cancer patients has been previously determined, and 6 
as expected, alpha-PVs were more often found in the cancer patients (49.0%) compared with 7 
the matched controls (12.0%) [11]. However, a study on a subset of the same cancer patients 8 
comparing tumor tissue and lavage specimens from the same patient has observed that the 9 
alpha-PV overall positivity rate is slightly lower in the rinse specimens than in tumor tissue 10 
specimens (53.0% vs 59.0%), with a greater diversity of types and multiple infection being 11 
more often found in the rinse specimens (12.0% vs 2.4%) [28]. The difference in alpha-PV 12 
positivity of oral cancer patients between tumor tissue and rinse specimens was more 13 
pronounced (16.7% vs 8.3%) in comparison with oropharyngeal cancer patients (67.5% vs 14 
62.4%). Similarly, more than double difference was found in beta-PV positivity of oral cancer 15 
patients between cancer tissue and rinse samples (55.2% vs 17.7%). On the other hand, in 16 
oropharyngeal cancer patients, unlike the alpha-PVs, the beta-PVs were less prevalent in 17 
tissue samples (45.7%) than in the rinse samples (60%). The co-positivity rates for alpha- and 18 
beta-types were 1%, 6%, 10%, and 29% in controls, oral cancers, oral lesions, and 19 
oropharyngeal cancers, respectively, but with no correlation (correlation coefficients ranged 20 
from -0.2 to 0.09, without statistical significance) (Table 3). 21 
 22 
 23 
17 
 
 
Table 3. Positivity of controls and patients with oral/oropharyngeal tumors for HPVs of alpha 1 
and beta-genera. 2 
   
Alpha-HPV 
N [%]* 
Overall HPV 
prevalence [%] 
 
Group of subjects N Positive Negative Alpha Beta 
Beta-
HPV 
N [%] 
Controls 67 5 62 7.5 56.7 
Positive 38 1 (1.5) 37 (55.2) 
  Negative 29 4 (6.0) 25 (37.3) 
  Oral lesions 99 14 85 14.1 67.7 
Positive 67 10 (10.1) 57 (57.6)   
Negative 32 4 (4.0) 28 (28.3)   
Oral cancers 63 9 54 14.3 34.9 
Positive 22 4 (6.3) 18 (28.6)   
Negative 41 5 (7.9) 36 (57.1)   
Oropharyngeal 
cancers 70 41 29 58.6 52.9 
Positive 37 20 (28.6) 17 (24.3) 
  Negative 33 21 (30.0) 12 (17.1) 
  
*percentages were calculated on the sample group subtotal 3 
4 
18 
 
 
One of the limitations of the present study is the availability of different types of samples 1 
collected from cancer patients and the respective controls. However, prior studies often used 2 
the same types of clinical material [21] due to ethical and medical reasons preventing biopsy 3 
sampling of healthy subjects. Thus, our data are readily comparable to those from the 4 
previous studies in this regard. Furthermore, in our present study, we were able to compare 5 
the prevalence and type-specificity in two different types of the clinical material taken from 6 
the same patient. We have previously shown for Alpha PV types that while in tumor tissue, 7 
only HR HPV types are present and multiple infection is rare, in oral rinses, multiple infection 8 
is more frequent and also LR HPV types as a single infection can be detected. Nevertheless, 9 
in patients with HR HPV-positive tumors, a concordant HR HPV type was present in 97.0% 10 
of oral rinses, suggesting viral shedding from the tumor [29]. In contrast, the concordance was 11 
poor for Beta-PV types. We hypothesize that it is due to the non-etiological association of the 12 
Beta-PV types with studied type of cancers. It is important to note that the biggest difference 13 
in the two types of materials analyzed in cancer patients is that the oral rinse provides 14 
information about the presence of viruses in the whole oral and proximal part of the 15 
oropharyngeal area while tissue sections provide information of the presence of HPV types in 16 
the tumor itself and in its direct proximity.  17 
One of the major strengths of this study is the use of the optimized multiplex PCR/Luminex 18 
assay that can readily distinguish a large number of genotypes in a single sample. The 19 
previous methods based on sequencing of PCR amplicons generated by consensus primers 20 
were limited in this regard. 21 
In summary, this study assessed the presence of the so far understudied beta-PVs in HNC 22 
patients, matched controls, and subjects with oral lesions using the newest TS-MPG assay 23 
specifically designed to target beta-PVs. The most prevalent type was the probably 24 
19 
 
 
carcinogenic HPV5, while the second most common was HPV38. The third leading type was 1 
HPV122 that has been so far almost completely absent from the literature, and herein it was 2 
found to be statistically significantly associated with cancer, which might warrant further 3 
interest and study. Finally, poor HPV type concordance between patient matched lavage and 4 
tissue samples suggests that beta-PVs are not strongly etiologically linked to HNC, even if 5 
some associations are statistically significant. 6 
7 
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Figure 1. Beta-PVs detected in head and neck squamous cell carcinomas (HNC) and oral 1 
lesions (the control groups are age and sex matched to HNC patients).  2 
 3 
 4 
